124276-83-1

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-BROMO-PHENYL)-CYCLOPROPANECARBONITRILE serves as a versatile intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications, making it an essential component in drug discovery and medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 1-(3-BROMO-PHENYL)-CYCLOPROPANECARBONITRILE is utilized as a key intermediate in the production of agrochemicals. Its chemical properties enable the creation of compounds with pesticidal, herbicidal, or other agricultural applications, contributing to the development of effective solutions for crop protection and management.
Used in Organic Synthesis:
1-(3-BROMO-PHENYL)-CYCLOPROPANECARBONITRILE is employed as a valuable building block in organic synthesis. Its unique structure and reactivity make it suitable for various chemical reactions, allowing the formation of more complex molecules with diverse applications in different industries.
Used in Medicinal Chemistry Research:
1-(3-BROMO-PHENYL)-CYCLOPROPANECARBONITRILE's potential biological activity and role as a building block for complex molecules make 1-(3-BROMO-PHENYL)-CYCLOPROPANECARBONITRILE an important tool in medicinal chemistry research. It is used to explore new chemical entities and investigate their interactions with biological targets, contributing to the advancement of drug development and therapeutic strategies.

InChI:InChI=1/C10H8BrN/c11-9-3-1-2-8(6-9)10(7-12)4-5-10/h1-3,6H,4-5H2

Upstream product

• 31938-07-5 (3-bromophenyl)acetonitrile 
• 107-04-0 1-Bromo-2-chloroethane 
• 106-93-4 ethylene dibromide 
• 3132-99-8 m-bromobenzoic aldehyde 

Downstream Products

• 597563-13-8 1-(3-bromophenyl)cyclopropanecarboxamide 
• 886366-33-2 [1-(3-bromophenyl)cyclopropyl]methanol 
• 145691-66-3 Ethyl 3-(2-ethoxycarbonylethenyl)-5-hydroxymethylcinnamate 

Relevant academic research and scientific papers

Preparation method of arylcyclopropane compound

The present invention discloses a method for preparing an arylcyclopropane compound, 1.0eq phenylacetonitrile and 1.1eq 1-bromo-2-chloroethane as the starting material, N, N- dimethylacetamide as a solvent, solvent dosage of 10V, plus 2.5eq sodium hydride

Nickel-Catalyzed Favorskii-Type Rearrangement of Cyclobutanone Oxime Esters to Cyclopropanecarbonitriles

A nickel-catalyzed base-promoted rearrangement of cyclobutanone oxime esters to cyclopropanecarbonitriles was developed. The ring opening of cyclobutanone oxime esters occurs at the sterically less hindered side. A base-promoted nickelacyclobutane intermediate, formed in situ, is assumed to be involved in the formation of the product.

Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)-H Borylation of Cyclopropanes

We herein report an Ir-catalyzed enantioselective C(sp3)-H borylation of cyclopropanecarboxamides using a chiral bidentate boryl ligand for the first time. A variety of substrates with α-quaternary carbon centers could be compatible in this reaction to provide β-borylated products with good to excellent enantioselectivities. We have also demonstrated that the borylated products can be used as versatile precursors engaging in stereospecific transformations of C-B bonds, including the synthesis of a bioactive compound Levomilnacipran.

PD(II)-CATALYZED ENANTIOSELECTIVE C-H ARYLATION OF FREE CARBOXYLIC ACIDS

The invention includes procedures for stereoselective β-arylation of carboxylic acids having a β-carbon atom. For example, stereoselective arylation procedures include the following reactions: (I)

A NOVEL PROCESS FOR THE SYNTHESIS OF 1-ARYL-1-TRIFLUOROMETHYLCYCLOPROPANES

The present invention relates to a process for the manufacturing of 1-aryl-1-trifluoromethylcyclopropanes, which serve as intermediates for the manufacturing of calcium T channel blockers of the general formula (A) which are described in WO 2015/186056.

Pd(II)-Catalyzed Enantioselective C(sp3)-H Arylation of Free Carboxylic Acids

A monoprotected aminoethyl amine chiral ligand based on an ethylenediamine backbone was developed to achieve Pd-catalyzed enantioselective C(sp3)-H arylation of cyclopropanecarboxylic and 2-aminoisobutyric acids without using exogenous directing groups. This new chiral catalyst affords new disconnection for preparing diverse chiral carboxylic acids from simple starting materials that are complementary to the various ring forming approaches.

Rhodium-Catalyzed Enantioselective Silylation of Cyclopropyl C?H Bonds

Hydrosilyl ethers, generated in situ by the dehydrogenative silylation of cyclopropylmethanols with diethylsilane, undergo asymmetric, intramolecular silylation of cyclopropyl C?H bonds in high yields and with high enantiomeric excesses in the presence of

Meta-selective C-H functionalization using a nitrile-based directing group and cleavable Si-tether

A nitrile-based template that enables meta-selective C-H bond functionalization was developed. The template is applicable to a range of substituted arenes and tolerates a variety of functional groups. The directing group uses a silicon atom for attachment

NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE

Disclosed is a compound represented by the general formula (1) or a salt thereof. The compound or a salt thereof has an inhibitory activity on IKKβ and is therefore useful as preventive and/or therapeutic agent for a disease associated with IKKβ. In the formula, R1 represents a hydrogen atom, a lower alkyl group, an aryl group, a hydroxy group, or the like; R2 represents a halogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, or the like; and m represents 0, 1, 2, or the like.

CATHEPSIN CYSTEINE PROTEASE INHIBITORS

This invention relates to a novel class of compounds, represented by the formula below, wherein the meanings of G, E, E, n, R1, R2, R3 et R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.